Vestronidase Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Vestronidase Alfa. Educational only — not medical advice.
Labeled uses
MEPSEVII is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome). Limitations of Use The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined.
Source: FDA labeling via NIH DailyMed (set 925d4e21…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.